326
Participants
Start Date
February 28, 2006
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2010
Oseltamivir
Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
Changi General Hospital, Singapore
National University Hospital, National University of Singapore, Singapore
Tan Tock Seng Hospital, Singapore
Queen Sirikit National Institute of Child Health, Bangkok
Siriraj Hospital Mahidol University, Bangkok
Bamrasnaradura Infectious Disease Institute, Nonthaburi
Chest Disease Institute, Nonthaburi
National Hospital of Pediatrics, Hanoi
National Institute fof Infectious and Tropical Diseases, Hanoi
Children's Hospital #1, Ho Chi Minh City
Hospital for Tropical Diseases, Ho Chi Minh City
Pediatric Hospital #2, Ho Chi Minh City
Wellcome Trust
OTHER
World Health Organization
OTHER
University of Oxford
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH